Identification and deconvolution of cross-resistance signals from antimalarial compounds using multidrug-resistant plasmodium falciparum strains

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 2, 2015, Pages 1110-1118

  Chugh, Monika ^a   Scheurer, Christian ^b,c   Sax, Sibylle ^b,c   Bilsland, Elizabeth ^d,i   Van Schalkwyk, Donelly A ^e   Wicht, Kathryn J ^f   Hofmann, Natalie ^b,c   Sharma, Anil ^a   Bashyam, Sridevi ^g   Singh, Shivendra ^g   Oliver, Stephen G ^d   Egan, Timothy J ^f   Malhotra, Pawan ^a   Sutherland, Colin J ^e   Beck, Hans Peter ^b,c   Wittlin, Sergio ^b,c   Spangenberg, Thomas ^h   Ding, Xavier C ^h  

^a INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

^b SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^c UNIVERSITY OF BASEL   (Switzerland)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^f UNIVERSITY OF CAPE TOWN   (South Africa)

^g SYNGENE INTERNATIONAL LTD   (India)

^h UNIVERSITY OF CAMPINAS   (Brazil)

ⁱ Medicines for Malaria Venture   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,4 OXADIAZOLE DERIVATIVE; ANTIMALARIAL AGENT; CHLOROQUINE; DIAZEPAM DERIVATIVE; ENZYME INHIBITOR; FALCIPAIN 2; PIPERIDINE DERIVATIVE;

ANTIMALARIAL ACTIVITY; ARTICLE; CASE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS RESISTANCE; DRUG ACTIVITY; DRUG MECHANISM; GENE; GENE SEQUENCE; GENOTYPE; HIGH THROUGHPUT SCREENING; HUMAN; IN VITRO STUDY; MOLECULAR BIOLOGY; MULTIDRUG RESISTANCE; NONHUMAN; PFCRT GENE; PHENOTYPE; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; DRUG SENSITIVITY; METABOLISM; PHYSIOLOGY;

ANTIMALARIALS; DRUG RESISTANCE; PARASITIC SENSITIVITY TESTS; PLASMODIUM FALCIPARUM;

EID: 84921786340     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03265-14     Document Type: Article

References (52)

1. Bilsland E, Pir P, Gutteridge A, Johns A, King RD, Oliver SG. 2011. Functional expression of parasite drug targets and their human orthologs in yeast. PLoS Negl Trop Dis 5:e1320. http://dx.doi.org/10.1371/journal .pntd.0001320.
2. Roberts L, Enserink M. 2007. Malaria. Did they really say . . . eradication? Science 318:1544 -1545. http://dx.doi.org/10.1126/science.318 .5856.1544.
3. Cotter C, Sturrock HJW, Hsiang MS, Liu J, Phillips AA, Hwang J, Gueye CS, Fullman N, Gosling RD, Feachem RGA. 2013. The changing epidemiology of malaria elimination: new strategies for new challenges. Lancet 382:900-911. http://dx.doi.org/10.1016/S0140-6736(13)60310-4.
4. Noor AM, Kinyoki DK, Mundia CW, Kabaria CW, Mutua JW, Alegana VA, Fall IS, Snow RW. 2014. The changing risk of Plasmodium falciparum malaria infection in Africa: 2000-10: a spatial and temporal analysis of transmission intensity. Lancet 383:1739-1747. http://dx.doi.org/10 .1016/S0140-6736(13)62566-0.
5. Garí E, Piedrafita L, Aldea M, Herrero E. 1997. A set of vectors with a tetracycline-regulatable promoter system for modulated gene expression in Saccharomyces cerevisiae. Yeast 13:837-848. http://dx.doi.org/10.1002 /(SICI)1097-0061(199707)13:9-837::AID-YEA145-3.0.CO;2-T.
6. World Health Organization. 2010. Global report on antimalarial drug efficacy and drug resistance: 2000-2010, p 121. World Health Organization, Geneva, Switzerland.
7. World Health Organization Global Malaria Programme. 2013. World malaria report 2013, p 1-284. World Health Organization, Geneva, Switzerland.
8. Carter MD, Phelan VV, Sandlin RD, Bachmann BO, Wright DW. 2010. Lipophilic mediated assays for beta-hematin inhibitors. Comb Chem High Throughput Screen 13:285-292. http://dx.doi.org/10.2174/1386207 10790980496.
9. Sandlin RD, Carter MD, Lee PJ, Auschwitz JM, Leed SE, Johnson JD, Wright DW. 2011. Use of the NP-40 detergent-mediated assay in discovery of inhibitors of -hematin crystallization. Antimicrob Agents Chemother 55:3363-3369. http://dx.doi.org/10.1128/AAC.00121-11.
10. Ncokazi KK, Egan TJ. 2005. A colorimetric high-throughput betahematin inhibition screening assay for use in the search for antimalarial compounds. Anal Biochem 338:306-319. http://dx.doi.org/10.1016/j.ab .2004.11.022.
11. Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR. 2002.Epidemiology of drug-resistant malaria. Lancet Infect Dis 2:209-218.http://dx.doi.org/10.1016/S1473-3099(02)00239-6.
12. Mita T, Tanabe K, Kita K. 2009. Spread and evolution of Plasmodium falciparum drug resistance. Parasitol Int 58:201-209. http://dx.doi.org/10 .1016/j.parint.2009.04.004.
13. Lu W-J, Wicht KJ, Wang L, Imai K, Mei Z-W, Kaiser M, Sayed El IET, Egan TJ, Inokuchi T. 2013. Synthesis and antimalarial testing of neocryptolepine analogues: addition of ester function in SAR study of 2,11- disubstituted indolo[2,3-b]quinolines. Eur J Med Chem 64:498-511.http://dx.doi.org/10.1016/j.ejmech.2013.03.072.
14. Trape JF. 2001. The public health impact of chloroquine resistance in Africa. Am J Trop Med Hyg 64:12-17.
15. Ding XC, Ubben D, Wells TN. 2012. A framework for assessing the risk of resistance for anti-malarials in development. Malar J 11:292. http://dx .doi.org/10.1186/1475-2875-11-292.
16. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM, Artemisinin Resistance in Cambodia 1 (ARC1) Study Consortium.2008. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med 359:2619-2620. http://dx.doi.org/10.1056/NEJMc0805011.
17. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NPJ, Lindegardh N, Socheat D, White NJ. 2009. Artemisinin resistance in Plasmodium falciparum malaria.NEngl J Med 361:455-467. http://dx.doi.org/10.1056/NEJMoa0808859.
18. Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, Sreng S, Anderson JM, Mao S, Sam B, Sopha C, Chuor CM, Nguon C, Sovannaroth S, Pukrittayakamee S, Jittamala P, Chotivanich K, Chutasmit K, Suchatsoonthorn C, Runcharoen R, Hien TT, Thuy-Nhien NT, Thanh NV, Phu NH, Htut Y, Han K-T, Aye KH, Mokuolu OA, Olaosebikan RR, Folaranmi OO, Mayxay M, Khanthavong M, Hongvanthong B, Newton PN, Onyamboko MA, Fanello CI, Tshefu AK, Mishra N, Valecha N, Phyo AP, Nosten F, Yi P, Tripura R, Borrmann S, Bashraheil M, Peshu J, Faiz MA, Ghose A, Hossain MA, Samad R, et al. 2014. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 371: 411-423. http: //dx.doi.org/10.1056/NEJMoa1314981.
19. Rogers WO, Sem R, Tero T, Chim P, Lim P, Muth S, Socheat D, Ariey F, Wongsrichanalai C. 2009. Failure of artesunate-mefloquine combination therapy for uncomplicated Plasmodium falciparum malaria in southern Cambodia. Malar J 8:10. http://dx.doi.org/10.1186/1475-2875-8-10.
20. Leang R, Barrette A, Bouth DM, Menard D, Abdur R, Duong S, Ringwald P. 2013. Efficacy of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax in Cambodia, 2008 to 2010. Antimicrob Agents Chemother 57:818-826. http://dx.doi.org/10.1128/AAC.00686-12.
21. Carrara VI, Lwin KM, Phyo AP, Ashley E, Wiladphaingern J, Sriprawat K, Rijken M, Boel M, McGready R, Proux S, Chu C, Singhasivanon P, White N, Nosten F. 2013. Malaria burden and artemisinin resistance in the mobile and migrant population on the Thai-Myanmar border, 1999- 2011: an observational study. PLoS Med 10:e1001398. http://dx.doi.org /10.1371/journal.pmed.1001398.
22. Bustos MD, Wongsrichanalai C, Delacollette C, Burkholder B. 2013. Monitoring antimalarial drug efficacy in the greater Mekong subregion: an overview of in vivo results from 2008 to 2010. Southeast Asian J Trop Med Public Health 44(Suppl 1):S201-S230.
23. Saunders DL, Vanachayangkul P, Lon C, U.S. Army Military Malaria Research Program, National Center for Parasitology, Entomology, and Malaria Control (CNM), Royal Cambodian Armed Forces. 2014. Dihy-droartemisinin- piperaquine failure in Cambodia. N Engl J Med 371:484-485. http://dx.doi.org/10.1056/NEJMc1403007.
24. Avery VM, Bashyam S, Burrows JN, Duffy S, Papadatos G, Puthukkuti S, Sambandan Y, Singh S, Spangenberg T, Waterson D, Willis P. 2014. Screening and hit evaluation of a chemical library against blood-stage Plasmodium falciparum. Malar J 13:190. http://dx.doi.org/10.1186/1475 -2875-13-190.
25. Dondorp AM, Ringwald P. 2013. Artemisinin resistance is a clear and present danger. Trends Parasitol 29:359-360. http://dx.doi.org/10.1016/j .pt.2013.05.005.
26. Martin SK, Oduola AM, Milhous WK. 1987. Reversal of chloroquine resistance in Plasmodium falciparum by verapamil. Science 235:899-901. http://dx.doi.org/10.1126/science.3544220.
27. Rottmann M, McNamara C, Yeung BKS, Lee MCS, Zou B, Russell B, Seitz P, Plouffe DM, Dharia NV, Tan J, Cohen SB, Spencer KR, Gonzalez-Paez GE, Lakshminarayana SB, Goh A, Suwanarusk R, Jegla T, Schmitt EK, Beck HP, Brun R, Nosten F, Renia L, Dartois V, Keller TH, Fidock DA, Winzeler EA, Diagana TT. 2010. Spiroindolones, a potent compound class for the treatment of malaria. Science 329:1175-1180. http://dx.doi.org/10.1126/science.1193225.
28. McNamara CW, Lee MCS, Lim CS, Lim SH, Roland J, Nagle A, Simon O, Yeung BKS, Chatterjee AK, McCormack SL, Manary MJ, Zeeman A-M, Dechering KJ, Kumar TRS, Henrich PP, Gagaring K, Ibanez M, Kato N, Kuhen KL, Fischli C, Rottmann M, Plouffe DM, Bursulaya B, Meister S, Rameh L, Trappe J, Haasen D, Timmerman M, Sauerwein RW, Suwanarusk R, Russell B, Rénia L, Nosten F, Tully DC, Kocken CHM, Glynne RJ, Bodenreider C, Fidock DA, Diagana TT, Winzeler EA. 2013. Targeting Plasmodium PI(4)K to eliminate malaria. Nature 504:248-253. http://dx.doi.org/10.1038/nature12782.
29. Meister S, Plouffe DM, Kuhen KL, Bonamy GMC, Wu T, Barnes SW, Bopp SE, Borboa R, Bright AT, Che J, Cohen S, Dharia NV, Gagaring K, Gettayacamin M, Gordon P, Groessl T, Kato N, Lee MCS, Mc- Namara CW, Fidock DA, Nagle A, Nam T-G, Richmond W, Roland J, Rottmann M, Zhou B, Froissard P, Glynne RJ, Mazier D, Sattabongkot J, Schultz PG, Tuntland T, Walker JR, Zhou Y, Chatterjee A, Diagana TT, Winzeler EA. 2011. Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. Science 334:1372-1377. http://dx.doi.org/10.1126/science.1211936.
30. van Schalkwyk DA, Burrow R, Henriques G, Gadalla NB, Beshir KB, Hasford C, Wright SG, Ding XC, Chiodini PL, Sutherland CJ. 2013. Culture-adapted Plasmodium falciparum isolates from UK travellers: in vitro drug sensitivity, clonality and drug resistance markers. Malar J 12:320. http://dx.doi.org/10.1186/1475-2875-12-320.
31. Burrows JN, van Huijsduijnen RH, Möhrle JJ, Oeuvray C, Wells TNC.2013. Designing the next generation of medicines for malaria control and eradication. Malar J 12:187. http://dx.doi.org/10.1186/1475-2875-12-187.
32. Ecker A, Lehane AM, Clain J, Fidock DA. 2012. PfCRT and its role in antimalarial drug resistance. Trends Parasitol 28:504-514. http://dx.doi .org/10.1016/j.pt.2012.08.002.
33. Summers RL, Nash MN, Martin RE. 2012. Know your enemy: understanding the role of PfCRT in drug resistance could lead to new antimalarial tactics. Cell Mol Life Sci 69:1967-1995. http://dx.doi.org/10.1007 /s00018-011-0906-0.
34. Chugh M, Sundararaman V, Kumar S, Reddy VS, Siddiqui WA, Stuart KD, Malhotra P. 2013. Protein complex directs hemoglobin-tohemozoin formation in Plasmodium falciparum. Proc Natl Acad SciUSA 110:5392-5397. http://dx.doi.org/10.1073/pnas.1218412110.
35. Trager W, Jensen JB. 1976. Human malaria parasites in continuous culture. Science 193:673-675. http://dx.doi.org/10.1126/science.781840.
36. Desjardins RE, Canfield C, Haynes J, Chulay J. 1979. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob Agents Chemother 16:710-718. http://dx .doi.org/10.1128/AAC.16.6.710.
37. Snyder C, Chollet J, Santo Tomas J, Scheurer C, Wittlin S. 2007. In vitro and in vivo interaction of synthetic peroxide RBx11160 (OZ277) with piperaquine in Plasmodium models. Exp Parasitol 115:296-300. http://dx .doi.org/10.1016/j.exppara.2006.09.016.
38. Fidock DA, Rosenthal PJ, Croft SL, Brun R, Nwaka S. 2004. Antimalarial drug discovery: efficacy models for compound screening. Nat Rev Drug Discov 3:509-520. http://dx.doi.org/10.1038/nrd1416.
39. Price RN, Uhlemann A-C, Brockman A, McGready R, Ashley E, Phaipun L, Patel R, Laing K, Looareesuwan S, White NJ, Nosten F, Krishna S. 2004. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet 364:438-447. http://dx.doi .org/10.1016/S0140-6736(04)16767-6.
40. Basco LK, Ringwald P. 2001. Analysis of the key pfcrt point mutation and in vitro and in vivo response to chloroquine in Yaoundé, Cameroon. J Infect Dis 183:1828-1831. http://dx.doi.org/10.1086/320726.
41. Egan TJ, Chen JY-J, de Villiers KA, Mabotha TE, Naidoo KJ, Ncokazi KK, Langford SJ, McNaughton D, Pandiancherri S, Wood BR. 2006. Haemozoin (beta-haematin) biomineralization occurs by self-assembly near the lipid/water interface. FEBS Lett 580:5105-5110. http://dx.doi.org /10.1016/j.febslet.2006.08.043.
42. Sá JM, Twu O, Hayton K, Reyes S, Fay MP, Ringwald P, Wellems TE.2009. Geographic patterns of Plasmodium falciparum drug resistance distinguished by differential responses to amodiaquine and chloroquine. Proc Natl Acad Sci U S A 106:18883-18889. http://dx.doi.org/10.1073 /pnas.0911317106.
43. Tan-ariya, P, Brockelman CR, Menabandhu C. 1987. Optimal concentration of p-aminobenzoic acid and folic acid in the in vitro assay of antifolates against Plasmodium falciparum. Am J Trop Med Hyg 37:42-48.
44. Ekland EH, Fidock DA. 2008. In vitro evaluations of antimalarial drugs and their relevance to clinical outcomes. Int J Parasitol 38:743-747. http: //dx.doi.org/10.1016/j.ijpara.2008.03.004.
45. Witkowski B, Khim N, Chim P, Kim S, Ke S, Kloeung N, Chy S, Duong S, Leang R, Ringwald P, Dondorp AM, Tripura R, Benoit-Vical F, Berry A, Gorgette O, Ariey F, Barale J-C, Mercereau-Puijalon O, Menard D.2013. Reduced artemisinin susceptibility of Plasmodium falciparum ring stages in western Cambodia. Antimicrob Agents Chemother 57:914-923. http://dx.doi.org/10.1128/AAC.01868-12.
46. Witkowski B, Amaratunga C, Khim N, Sreng S, Chim P, Kim S, Lim P, Mao S, Sopha C, Sam B, Anderson JM, Duong S, Chuor CM, Taylor WRJ, Suon S, Mercereau-Puijalon O, Fairhurst RM, Menard D. 2013. Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo drugresponse studies. Lancet Infect Dis 13:1043-1049. http://dx.doi.org/10 .1016/S1473-3099(13)70252-4.
47. Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois A-C, Khim N, Kim S, Duru V, Bouchier C, Ma L, Lim P, Leang R, Duong S, Sreng S, Suon S, Chuor CM, Bout DM, Ménard S, Rogers WO, Genton B, Fandeur T, Miotto O, Ringwald P, Le Bras J, Berry A, Barale J-C, Fairhurst RM, Benoit-Vical F, Mercereau-Puijalon O, Menard D. 2014. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 505:50-55. http://dx.doi.org/10.1038/nature12876.
48. Nair S, Miller B, Barends M, Jaidee A, Patel J, Mayxay M, Newton P, Nosten F, Ferdig MT, Anderson TJC. 2008. Adaptive copy number evolution in malaria parasites. PLoS Genet 4:e1000243. http://dx.doi.org /10.1371/journal.pgen.1000243.
49. Koenderink JB, Kavishe RA, Rijpma SR, Russel FGM. 2010. The ABCs of multidrug resistance in malaria. Trends Parasitol 26:440-446. http://dx .doi.org/10.1016/j.pt.2010.05.002.
50. Leroy D, Campo B, Ding XC, Burrows JN, Cherbuin S. 2014. Defining the biology component of the drug discovery strategy for malaria eradication. Trends Parasitol 30:478-490. http://dx.doi.org/10.1016/j.pt.2014.07 .004.
51. Ettari R, Bova F, Zappalà M, Grasso S, Micale N. 2010. Falcipain-2 inhibitors. Med Res Rev 30:136-167. http://dx.doi.org/10.1002/med .20163.
52. Rosenthal PJ, McKerrow JH, Aikawa M, Nagasawa H, Leech JH. 1988. A malarial cysteine proteinase is necessary for hemoglobin degradation by Plasmodium falciparum. J Clin Invest 82:1560-1566. http://dx.doi.org/10 .1172/JCI113766.